Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
August 15, 2017
VentureMed Group Raises $15 Million Series B Equity Financing

October 28, 2016
New data on EndoStim® therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at United European Gastroenterology Week 2016

October 19, 2016
Sophia Genetics, spécialisée dans la bio-informatique, vise les Etats-Unis

October 9, 2016
Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies

September 13, 2016
Sophia Genetics and Illumina Sign Co-Marketing Agreement to Speed Adoption of Next-Generation Sequencing (NGS) in Clinical Diagnostics

November 26, 2015
Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis

September 2, 2015
Molecular Partners 1H 2015 Release

September 1, 2015
CeQur Announces $100 Million Series C Financing

September 1, 2015
Symetis announces intention to float on SIX Swiss Exchange

August 26, 2015
ReShape Medical, Inc. Completes $38 Million Series D Financing Round Led by HealthCor Partners Management, L.P. and Endeavour Vision SA to Support U.S. Commercialization of ReShape™ Integrated Dual Balloon System Following Recent Approval by the FDA.

July 22, 2015
GYNESONICS RAISES $43 MILLION IN EQUITY FINANCING - Endeavour Vision and Abingworth Lead Funding

July 21, 2015
Allergan strengthens DARPin development and discovery alliance with Molecular Partners

July 7, 2015
First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment

May 19, 2015
CeQur Announces Publication Of Study Results On PaQ® Insulin Delivery Device To Reduce Barriers To Insulin Therapy

May 8, 2015
CeQur Announces Publication of Data Demonstrating PaQ® Insulin Delivery Device Reduces Barriers to Insulin Therapy

April 27, 2015
Medtech Investing: Making Late-Stage Deal Pay
April 23, 2015
L’étoile montante des medtech suisses

March 17, 2015
Molecular Partners reports its results for the Financial Year 2014 ‐  A transformative year for the company

March 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

March 10, 2015
BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

December 18, 2014
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

December 5, 2014
Total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option

December 4, 2014
PneumRx Acquired by BTG plc for up to USD 475 Million

November 6, 2014
Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange

November 6, 2014
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

October 8, 2014
Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share – First trading day expected for 22 October 2014

October 6, 2014
Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio

September 23, 2014
Molecular Partners launches IPO on SIX Swiss Exchange

September 22, 2014
FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014

September 12, 2014
Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations

September 2, 2014
Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing

July 8, 2014
Sophia Genetics raises Series B round led by Invoke Capital

July 1, 2014
Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program

June 19, 2014
Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant

April 10, 2014
CeQur Appoints Douglas Lawrence Chief Executive Officer

April 8, 2014
Epigenetic Cancer Therapy Clears Phase I

March 5, 2014
Diabetes Care Publishes Data Demonstrating PaQ® Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes

January 8, 2014
CeQur to Present at the 32nd Annual J.P. Morgan Healthcare Conference

December 4, 2013
Roche and Molecular Partners enter into alliance to develop new cancer treatments

October 28, 2013
Symetis Announces a Symbolic Milestone - the 1000th Patient Implanted with ACURATE TA™

October 28, 2013
French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time

September 26, 2013
Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI

September 24, 2013
Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting

September 19, 2013
BIND Therapeutics Announces Pricing of Initial Public Offering

September 9, 2013
CeQur SA Closes $27 Million Series B Financing

August 27, 2013
BIND Recognized by the World Economic Forum as a Technology Pioneer

August 19, 2013
BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

August 12, 2013
BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

August 12, 2013
Symetis announces successful, first time implantation of i ts ACURATE TA™ and ACURATE TF™ TAVI systems in Japan

April 3, 2013
Symetis' ACURATE TA(TM) Confirms Superior Results

February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

April 13, 2010
CeQur SA names Robert O'Holla EVP for Regulatory Affairs

Zurich‐Schlieren, July 21, 2015. Molecular Partners AG (ticker: MOLN) today announced that Allergan, Inc. has reinforced its broad commitment to the discovery, research and development of multiple DARPin‐based products in ophthalmology in collaboration with Molecular Partners. The collaboration includes a multi‐VEGF/PDGF DARPin currently in preclinical development and several additional discovery programs. Abicipar, a long‐acting VEGF antagonist, for which Phase III development was recently initiated, was the first DARPin in the partnership.

In connection with its strengthened commitment to the DARPin research and discovery alliance, Allergan has agreed to make accelerated milestone payments of USD 35 million. 

Furthermore, Molecular Partners is entitled to receive additional payments and certain success based milestone payments from Allergan in connection with abicipar, the multi‐VEGF/PDGF DARPin and additional discovery programs. Thi ...

© Endeavour Vision SA 2006-2017 Terms & Conditions